The weight-loss ripple effect

Metabolic medicine will reshape healthcare.

By Sam Rivera

What’s inside

• LLY Eli Lilly: Metabolic disease medicines; ~61% US GLP-1 share and retatrutide nearing surgery-level results
• NVO Novo Nordisk: Diabetes and obesity medicines; Wegovy pill launch with 600,000+ patients defends the pill lead
• AMGN Amgen: Biotechnology and metabolic drug development; the credible third entrant in obesity
• VRTX Vertex: Drug discovery and development; disciplined pipeline builder expanding beyond its first franchise
• PFE Pfizer: Named with Lilly and Novo as the third big pharma chasing the next obesity drugs
• TMO Thermo Fisher: Life-science tools and manufacturing services; contract capacity for peptide scale-up
• DHR Danaher: Diagnostics and life-science equipment; bioprocessing demand rises with obesity drug volumes
• WST West Pharmaceutical Services: Injectable delivery components scale directly with GLP-1 pen and vial volumes
• ABT Abbott: Medical devices and diagnostics; continuous glucose sensing becomes mainstream metabolic tracking
• DXCM Dexcom: Glucose monitoring pairs with drug therapy as metabolic care becomes continuous
• MDT Medtronic: Medical technology and devices; diabetes and cardiometabolic franchises track the shift

Why it could work

Metabolic medicine will reshape healthcare. The basket combines direct participants and broader suppliers.

What could break it

Adoption could disappoint, competition could weaken margins, or high valuations could already price in the trend. Some holdings are broad, indirect proxies.

For learning only. Not investment advice.